Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L, Danese I, Magistrelli E, Colangeli V, Manfredi R, Bon I, Re MC, Conti M, Viale P. Calza L, et al. Among authors: re mc. HIV Clin Trials. 2016 Feb;17(1):38-47. doi: 10.1080/15284336.2015.1122874. Epub 2016 Jan 5. HIV Clin Trials. 2016. PMID: 26728706
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy.
Calza L, Colangeli V, Magistrelli E, Contadini I, Bon I, Re MC, Conti M, Mancini R, Viale P. Calza L, et al. Among authors: re mc. AIDS Res Hum Retroviruses. 2017 Feb;33(2):126-132. doi: 10.1089/AID.2016.0134. Epub 2016 Oct 14. AIDS Res Hum Retroviruses. 2017. PMID: 27618139
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Calza L, Magistrelli E, Colangeli V, Borderi M, Bussini L, Bon I, Re MC, Viale P. Calza L, et al. Among authors: re mc. Infect Dis (Lond). 2017 Oct;49(10):737-747. doi: 10.1080/23744235.2017.1339325. Epub 2017 Jul 6. Infect Dis (Lond). 2017. PMID: 28683645
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L, Cafaggi M, Colangeli V, Borderi M, Barchi E, Lanzafame M, Nicole' S, Degli Antoni AM, Bon I, Re MC, Viale P. Calza L, et al. Among authors: re mc. Infect Dis (Lond). 2018 May;50(5):352-360. doi: 10.1080/23744235.2017.1410285. Epub 2017 Dec 6. Infect Dis (Lond). 2018. PMID: 29210336
284 results